Skin biology of aging
Skin aging is the visible expression of fibroblast senescence, collagen and elastin loss, basement membrane degradation, and reduced epidermal turnover. By age 60, dermal collagen has typically declined 30–40% from young-adult baseline. Wound healing slows, dermal thickness reduces, and the skin's barrier function degrades. The peptide approaches address two leverage points: stimulating fibroblast activity (collagen synthesis) and supporting the vascular bed that feeds dermal repair (angiogenesis).
GHK-Cu
GHK-Cu — the human copper tripeptide glycyl-histidyl-lysine bound to copper — was discovered by Loren Pickart in the 1970s and has the deepest cosmeceutical research base of any peptide. It functions as a growth-factor mimetic at the dermal fibroblast level, upregulating collagen, elastin, glycosaminoglycan, and dermal proteoglycan synthesis. It also drives angiogenesis at the wound interface and accelerates re-epithelialization (Pickart, Biochem Soc Trans, 2008, PMID: 19021507; Pickart and Margolina, Int J Mol Sci, 2018, PMID: 30115825).
Topical 1–3% formulations show clinical-grade improvements in fine lines, dermal thickness, skin elasticity, and wound healing over 12-week protocols. Subcutaneous administration extends these effects systemically — though direct evidence for systemic GHK-Cu skin benefits is mostly anecdotal. The most reliable protocol combines topical GHK-Cu daily with intermittent SC dosing.
BPC-157
Systemic BPC-157 accelerates skin wound healing in rodent models (Sikiric et al., extensive review literature) and is used clinically — informally — for post-surgical scar improvement and chronic non-healing wound support. It pairs particularly well with GHK-Cu: BPC-157 mobilizes systemic repair capacity, GHK-Cu directs that capacity at the wound bed.
Supporting peptides
TB-500 — cytoskeletal remodeling, useful for hypertrophic scar revision. KPV — anti-inflammatory; useful for inflammatory dermatoses (rosacea, eczema flares) and post-injury inflammation. Epitalon — secondary skin improvements via systemic mechanisms (improved sleep architecture, restored circadian).
Topical versus systemic
Topical peptides act locally on the dermis; they don't reach systemic circulation in meaningful amounts. This makes them safer (no systemic side effects) and more dose-efficient at the target site. The limit is that topical penetration is limited by formulation and skin barrier — even well-formulated GHK-Cu reaches the deep dermis at only a few percent of the applied concentration.
Subcutaneous administration reaches the systemic circulation and reaches every dermal fibroblast in the body. This is helpful for diffuse complaints (overall skin quality, dermal thickness, multiple lesion sites) but loses the dose-concentration advantage at any single site. The combination — topical for site-specific effect, systemic for diffuse — is the most reliable approach for serious dermal protocols.
Protocols
Beginner (topical-only, 12 weeks): GHK-Cu 1% topical cream applied twice daily after cleansing, to face, neck, and any specific concern areas. Photograph baseline and at 4, 8, 12 weeks. Subjective rating on skin texture, elasticity, and visible wrinkles.
Intermediate (topical + systemic, 12 weeks): Topical GHK-Cu as above. Add GHK-Cu 1 mg SC daily for 4 weeks, then 1 mg SC every other day for 8 weeks. Re-evaluate.
Wound or scar revision (8 weeks): GHK-Cu 1 mg SC near the wound site daily until re-epithelialization complete, then every other day for an additional 4 weeks. Topical GHK-Cu also applied. Concurrent BPC-157 500 mcg SC daily for systemic repair support.
Safety
GHK-Cu has an excellent safety profile in both topical and systemic use. Some people with copper sensitivity report topical irritation; patch-test first. Systemic GHK-Cu has no notable adverse events in published reports. The repair-promoting nature of these peptides means they should not be used in active malignancy without medical guidance.
References
- Pickart L. The human tri-peptide GHK and tissue remodeling. Biochem Soc Trans. 2008. PMID: 19021507.
- Pickart L, Margolina A. Regenerative and Protective Actions of the GHK-Cu Peptide. Int J Mol Sci. 2018. PMID: 30115825.
- Pickart L. The human tri-peptide GHK (glycyl-l-histidyl-l-lysine) and tissue remodeling. J Biomater Sci Polym Ed. 2008.
- Sikiric P, Seiwerth S, et al. Brain-gut axis and BPC 157. Curr Pharm Des. 2014.
Comparison to conventional dermatology
The dermatological cosmeceutical landscape includes retinoids (gold standard for fine lines and texture), vitamin C, niacinamide, AHAs, and increasingly stem-cell-conditioned media. Peptides — particularly GHK-Cu — slot into this landscape as a layer that targets dermal fibroblast activity specifically, which is complementary to the keratinocyte-focused mechanism of retinoids. The most effective dermatological protocols typically layer: retinoid for keratinization, GHK-Cu for dermal remodeling, sunscreen for photoprotection.
The clinical evidence for topical GHK-Cu in skin elasticity, fine lines, and dermal thickness is among the most rigorous in the cosmeceutical-peptide space — multiple controlled studies with histological endpoints, including basement membrane thickness changes visible on biopsy.
BPC-157 for skin — the systemic dimension
While BPC-157 is best known as a recovery peptide, the systemic effects on dermal wound healing, scar quality, and tissue regeneration overlap meaningfully with dermatological goals. Bodybuilders and athletes informally report improvements in skin quality after extended BPC-157 protocols. The published evidence here is again primarily preclinical — extensive rodent wound healing studies — with human evidence accumulating informally.
Timeline
Topical GHK-Cu typically produces visible improvement at 8 weeks (texture), 12 weeks (fine lines), 16+ weeks (dermal thickness on biopsy). Photograph consistently for objective tracking. Stack with retinoid (alternate nights to avoid irritation) and daily sunscreen for the highest-impact dermatological-peptide protocol available.